Latest Biochemistry of Alzheimer's disease Stories
An international team of Alzheimerâ€™s disease experts, led by Washington University School of Medicine in St. Louis, has uncovered a gene variation that appears to predict the rate at which Alzheimerâ€™s disease will progress.
In people with Alzheimer's, the brain becomes riddled with clumps of protein, forming what are known as amyloid plaques.
A team of scientists, led by University of California, San Diego School of Medicine researchers, has synthesized hundreds of new compounds with the potential of reducing the production of the A-beta 42 peptide, a primary component of Alzheimer's disease (AD).
In the Sept 9, 2010 issue of Neuron, Neurogenetic Pharmaceuticals, Inc. (NGP) reports proof of concept studies that show its proprietary compound, NGP 555, is effective in preventing the amyloid pathology of Alzheimer's disease (AD) in a transgenic mouse model.
High plasma levels of beta-amyloidâ€”protein fragments associated with Alzheimer's disease when they accumulate in the brainâ€”appear to be associated with faster cognitive decline even in those who do not develop dementia.
Higher concentrations of clusterin, a protein in the blood plasma, appears to be associated with the development, severity and progression of Alzheimer's disease.
Scientists discovered characteristic amyloid plaques in retinas from Alzheimer's disease patients and used a noninvasive optical imaging technique to detect retinal plaques in live laboratory mice.
Recent study documents the spread of a disease process thought to signal the onset of Alzheimer's disease.
Researchers at the University of Illinois have identified a potential drug target for the treatment of Alzheimerâ€™s disease: a receptor that is embedded in the membrane of neurons and other cells.
A major Australian study has provided new insights into the loss of structure in regions of the brain and its potential association with Alzheimerâ€™s Disease.
- Growing in low tufty patches.